Testosterone modulates mitochondrial aconitase in the full-length human androgen receptor-transfected PC-3 prostatic carcinoma cells.

In vitro studies indicated that dihydrotestosterone (DHT) stimulates the enzymatic activity of the mitochondrial aconitase (mACON) in androgen-sensitive prostatic carcinoma cells, LNCaP. Cell proliferation assay determined that DHT doubles the optimal proliferation response of LNCaP cells. The androgen-insensitive human prostatic carcinoma cells, PC-3, were overexpressed in the human androgen receptor to assess the involvement of the native androgen receptor in the regulation by DHT of mACON gene expression. A stable-transfected clone that expresses the full-length androgen receptor was selected and termed PCAR9. The results revealed that DHT-treated PCAR9 cells paradoxically not only reduced the enzymatic activity of mACON but also blocked the biosynthesis of intracellular ATP attenuating cell proliferation. Transient gene expression assay indicated that DHT divergently regulates the promoter activity of the mACON gene in LNCaP and PCAR9 cells. This study suggested that DHT regulates mACON gene expression and the proliferation of cells in a receptor-dependent model through modulation by unidentified non-receptor factors.

[1]  H. Juang.  Cyclic adenosine 3′,5′-monosphosphate mediate prolactin regulation of mitochondrial aconitase in human prostate carcinoma cells , 2004, Molecular and Cellular Endocrinology.

[2]  H. Juang.  Modulation of mitochondrial aconitase on the bioenergy of human prostate carcinoma cells. , 2004, Molecular genetics and metabolism.

[3]  J. White,et al.  Agonist-bound nuclear receptors: not just targets of coactivators. , 2003, Journal of molecular endocrinology.

[4]  D. Miao,et al.  Androgen regulation of parathyroid hormone-related peptide production in human prostate cancer cells. , 2003, Endocrinology.

[5]  Alexander Marks,et al.  Androgen modulation of adhesion and antiadhesion molecules in PC-3 prostate cancer cells expressing androgen receptor. , 2002, Endocrinology.

[6]  R. Franklin,et al.  Testosterone and prolactin regulation of metabolic genes and citrate metabolism of prostate epithelial cells. , 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[7]  N. McKenna,et al.  Minireview: Nuclear Receptor Coactivators-An Update. , 2002, Endocrinology.

[8]  N. McKenna,et al.  0013-7227/02/$15.00/0 Endocrinology 143(7):2461–2465 Printed in U.S.A. Copyright © 2002 by The Endocrine Society Minireview: Nuclear Receptor Coactivators—An Update , 2022 .

[9]  K. Nakashiro,et al.  Androgen receptor expression in androgen‐independent prostate cancer cell lines , 2001, The Prostate.

[10]  B. Haendler,et al.  Androgen receptor signalling: comparative analysis of androgen response elements and implication of heat-shock protein 90 and 14-3-3η , 2001, Molecular and Cellular Endocrinology.

[11]  K. Burnstein,et al.  Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. , 2000, Endocrinology.

[12]  G. Jenster,et al.  Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex. , 2000, Molecular endocrinology.

[13]  Chawnshang Chang,et al.  From Androgen Receptor to the General Transcription Factor TFIIH , 2000, The Journal of Biological Chemistry.

[14]  D. Robyr,et al.  Nuclear hormone receptor coregulators in action: diversity for shared tasks. , 2000, Molecular endocrinology.

[15]  K. Burnstein,et al.  Type 1 vasoactive intestinal peptide receptor expression in PC3/AR cells is evidence of prostate epithelial differentiation , 2000, The Prostate.

[16]  R. Shukin,et al.  Determinants of DNA sequence specificity of the androgen, progesterone, and glucocorticoid receptors: evidence for differential steroid receptor response elements. , 1999, Molecular endocrinology.

[17]  Bernhard O. Palsson,et al.  Cancer cell lines , 1999 .

[18]  C. López-Otín,et al.  Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. , 1998, Endocrine reviews.

[19]  E. Wilson,et al.  Transcriptional repression of the alpha-subunit gene by androgen receptor occurs independently of DNA binding but requires the DNA-binding and ligand-binding domains of the receptor. , 1997, Molecular endocrinology.

[20]  J. Trachtenberg,et al.  Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor , 1997, Molecular and Cellular Endocrinology.

[21]  M. Webber,et al.  Immortalized and tumorigenic adult human prostatic epithelial cell lines: Characteristics and applications part 2. Tumorigenic cell lines , 1997, The Prostate.

[22]  R. Hiipakka,et al.  Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Franklin,et al.  Testosterone and prolactin stimulation of mitochondrial aconitase in pig prostate epithelial cells. , 1996, Urology.

[24]  J. Drapier,et al.  Aconitases: a class of metalloproteins highly sensitive to nitric oxide synthesis. , 1996, Methods in enzymology.

[25]  R. Hiipakka,et al.  Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. , 1995, Cancer letters.

[26]  R. Franklin,et al.  Testosterone stimulates the biosynthesis of m-aconitase and citrate oxidation in prostate epithelial cells , 1995, Molecular and Cellular Endocrinology.

[27]  R. Franklin,et al.  Androgen Modulation of Multiple Transcription Start Sites of the Mitochondrial Aspartate Aminotransferase Gene in Rat Prostate (*) , 1995, The Journal of Biological Chemistry.

[28]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[29]  D. Horsfall,et al.  Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3 , 1995, Steroids.

[30]  R. Franklin,et al.  Bioenergetic theory of prostate malignancy , 1994, The Prostate.

[31]  G. Mills,et al.  Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. , 1993, Cancer research.

[32]  K. Ito,et al.  Expression and function of normal and LNCaP androgen receptors in androgen-insensitive human prostatic cancer cells. Altered hormone and antihormone specificity in gene transactivation. , 1991, Receptor.

[33]  R. Franklin,et al.  Concepts of citrate production and secretion by prostate 1. Metabolic relationships , 1991, The Prostate.

[34]  S. Liao,et al.  Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S. J. Higgins,et al.  The endocrinology and developmental biology of the prostate. , 1987, Endocrine reviews.

[36]  R. Franklin,et al.  The effect of testosterone on citrate synthesis and citrate oxidation and a proposed mechanism for regulation of net citrate production in prostate. , 1986, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[37]  H. Beinert,et al.  Mössbauer and EPR studies of activated aconitase: development of a localized valence state at a subsite of the [4Fe-4S] cluster on binding of citrate. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[38]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.

[39]  J. Lechner,et al.  Establishment and characterization of a human prostatic carcinoma cell line (PC-3). , 1979, Investigative urology.

[40]  W. Gruber,et al.  Determination of citrate with citrate lyase. , 1966, Analytical biochemistry.

[41]  L. Melstrom,et al.  Malignancy. , 1938, California and western medicine.